top of page

22nd Forum: 2023 Trends in New Drug Development


January 31, 2023

11:00 AM – 12:00 PM


Covid-19, drug pricing legislation and new technologies have transformed the biopharma industry during the last few years. New drug discovery and development has rapidly evolved with advancements in technology such as artificial intelligence (AI). However, the length, complexity and uncertainty of drug discovery coupled with current economic conditions pose a threat to continuing innovation in the global biopharma industry. In this webinar, renowned industry experts and leaders will address the 2023 drug development trends, challenges and prospects and discuss strategies to move forward.



Program

11:00AM - 12:00PM   Session

"2023 Trends in New Drug Development"

  • Tae-Wan Kim, Ph.D. | Associate Professor, Columbia University

  • Hyun Joo, Ph.D. | Principal Scientist/Director, Syntekabio

  • Kern Chang, Ph.D. | Scientific Integrator & Associate Director, Biotherapeutic Development and Supply of Janssen R&D (Johnson & Johnson Company)

  • John Duguid, Ph.D. | Managing Director, Auctus Capital Partners | Partner, BioConnexUS

  • Joseph McMenamin, MD, JD, (Moderator)  | CLO and EVP, W Medical Strategy Group 







Speaker Biography


Joesph McMenamin, MD, JD (Moderator)

CLO and EVP, W Medical Strategy Group 


Joseph McMenamin, M.D., J.D. practices law at McMenamin Law Offices, PLLC., in Richmond, Virginia. He is also CLO and EVP for WMSG. Joe has some 37 years’ experience in defending healthcare organizations and providers against a variety of allegations in state and federal court. He also has advised them on law applicable to Internet and marketing communications, digital health issues, augmented intelligence, the conduct of human research, informed consent, risk management, and regulatory and contract matters. Previously, he practiced emergency medicine for seven years at hospitals in Pennsylvania and Georgia.


Tae-Wan Kim, Ph.D.

Associate Professor, Columbia University


Tae-Wan Kim, Ph.D. is Laboratory Head and an Associate Professor in the Department of Pathology and Cell Biology and  Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, at Columbia University Irving Medical Center.  The laboratory of Dr. Kim conducts translational research aimed at discovering novel therapeutics for Alzheimer’s disease. Dr. Kim is a co-founder of Melanis Co. Ltd, which provides innovative diagnostic and therapeutic solutions to major human chronic diseases (Melanis is now BL Melanis, a subsidiary of BL PharmTech - a KOSDAQ company). He has consulted for a number of pharmaceutical companies worldwide facilitating inception of new bioventures and international licensing deals.


Hyun Joo, Ph.D.

Principal Scientist/Director, Syntekabio 


Hyun Joo, Ph.D. is an experienced computational structural bioinformatician with a demonstrated history of working as computational chemist and drug developer. Skilled in computational chemistry, bioinformatics, life sciences, molecular modeling, and protein/ligand design. He has a PhD in Computational Chemistry from Auburn University and teaching experiences in Chemistry and biophysical chemistry.


Kern Chang, Ph.D.

Principal Scientist/Director, Syntekabio 


Hyun Joo, Ph.D. is an experienced computational structural bioinformatician with a demonstrated history of working as computational chemist and drug developer. Skilled in computational chemistry, bioinformatics, life sciences, molecular modeling, and protein/ligand design. He has a PhD in Computational Chemistry from Auburn University and teaching experiences in Chemistry and biophysical chemistry.


John Duguid, Ph.D.

Managing Director, Auctus Capital Partners | Partner, BioConnexUS


John Duguid, Ph.D. has managed public and private equity investments in biotech and medtech for institutional and Ultra High Net worth (UHNW) investors for over two decades. He also spent a good deal of time consulting and raising capital for companies in this space. John brings multiple perspectives to the life sciences, including consulting, banking, investing and even practical research experience, where he previously worked as a senior scientist for a gene therapy company, finding solutions for drug formulation, characterization and drug delivery. He holds a PhD in biochemistry from the University of Minnesota, a BS in biomedical engineering from the University of Iowa and an MBA from Cornell University.



Comentários


bottom of page